Time to first decision: 6days
Review time: 52days
Submission to acceptance: 64days
Acceptance to publication: 6days

EJMECH (The European Journal of Medicinal Chemistry) is a global journal that publishes studies on the main aspects of medicinal chemistry. It provides a medium for publication of original research papers and it welcomes critical review papers.

A typical paper would report on the design (with or without the support of computational methods), organic synthesis, characterization and biochemical/pharmacological evaluation of novel, potent compounds preferentially with a clear (or proven) mechanism of action and/or target. Other topics of interest are molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present a clear rational for a study, provide insight into the strategy and design of compounds and into the mechanism of action, and biological targets. Manuscripts reporting only computational studies are out-of-scope unless a new method (broadly applicable, validated and available to the community) is reported. Authors are kindly invited to look to published articles for the scope of the journal and the organisation of papers.

Full papers
Review papers

Editor-in-Chief
H. Galons
Université Paris Descartes, Paris, France Email H. Galons
Associate Editors
L-H Zhang
Sch. of Pharmaceutical Sciences, Peking University, Beijing, China Email L-H Zhang
R. Csuk
Dept. of Chemistry, Martin Luther University Halle-Wittenberg, Halle (Saale), GermanyEmail R. Csuk
N. Moitessier
Chemistry Department, McGill University, Montreal, Quebec, Canada Email N. Moitessier
T. Jonckers
Janssen Pharmaceutica NV, Janssen Research & Development, Beerse, Belgium Email T. Jonckers
P. Barraja
Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), , Università degli Studi di Palermo, Palermo, Italy Email P. Barraja
P. Yu
College of Biotechnology, Tianjin University of Science and Technology, Tianjin, ChinaEmail P. Yu
Honorary Editor-in-Chief
O. Lafont
Faculté de Médecine et Pharmacie, Rouen, France
Editorial Advisory Board
C.W.G. Fishwick
University of Leeds, Leeds, UK
P. Furet
Novartis International AG, Basel, Switzerland
P. G. George
T. Guzi, VP Chemistry
Blueprint Medicines, Cambridge, Massachusetts, USA
D. Hadjipavlou-Litina
Aristotle University of Thessaloniki, Thessaloniki, Greece
R. Hawley
University of California at San Francisco (UCSF), San Francisco, California, USA
R. J-R. Hwu
National Tsing Hua University, Hsinchu, Taiwan
L.H. Jones
VP, Chemical Biology. Jnana Therapeutics, Boston, MA, USA
C. Kunick
Technische Universität Braunschweig, Braunschweig, Germany
C. Lasmezas
The Scripps Research Institute, Jupiter, Florida, USA
D. Lesuisse
Sanofi, Framingham, Massachusetts, USA
M. Lucas
Cubist Pharmaceuticals, Lexington, Massachusetts, USA
D. Neri
Swiss Federal Institute of Technology, Zurich, Switzerland
T. Owens
Principia Bioharma Inc., San Francisco, California, USA
M.-J. Pérez-Pérez
Instituto de Química Médica (IQM-CSIC), Madrid, Spain
J. Quan
Peking University, Beijing, China
K. Roy
Jadavpur University, Kolkata, India
J. K. Shen
Chinese Academy of Sciences (CAS), Shanghai, China
P. Singh
Guru Nanak Dev University, Amritsar, India
C.T. Supuran
Università degli Studi di Firenze, Sesto Fiorentino (Firenze), Italy
T.T. Talele
St. John's University, Queens, New York, USA
Y.-M. Zhang
Université Pierre et Marie Curie, Paris, France
D. M. Zou
Peking University, Beijing, China